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Abstract The purpose of this study was to determine if
receipt of chemotherapy was associated with utilization of
the 21-gene recurrence score assay (RS assay) or with
recurrence score (RS) in eligible patients. Using theNational
Cancer Data Base (NCDB), we identified female patients
eligible for RS assay based on National Comprehensive
Cancer Network (NCCN) guidelines: age 18–70, ER-posi-
tive and HER2-negative early-stage breast cancer diagnosed
during 2010–2013.We excluded patients notmeeting testing
guidelines. Inclusion required result of RS in patients who
underwent RS assay and status for receipt of chemotherapy.
Multivariable logistic regression models and propensity
matched analysis were used to determine associations
between RS assay and RS with receipt of chemotherapy.
Among 129,765 patients who were eligible, 74,778 under-
went RS assay and had results available. Of these, 59.5 %
(44,505) had low-risk, 32.0 % (23,920) had intermediate-
risk, and 8.5 % (6353) had high-risk RS. Patients with
intermediate- and high-risk RS were more likely to receive
chemotherapy [OR 12.9 (CI 12.2–13.6), p\0.001 and OR
87.2 (CI 79.6–95.6), p\0.0001], respectively. In both low-
and intermediate-risk groups, increasing RS score was sig-
nificantly associated with increasing odds of receiving
chemotherapy [OR 1.10 (CI 1.09–1.12), p\0.0001 and OR
1.26 (CI 1.25–1.27), p\0.0001, respectively, for each point
increase in RS]. Receipt of chemotherapy was more likely in
patients who did not undergo RS assay compared to those
who did, OR 1.21 (CI 1.175–1.249) p\0.0001. The uti-
lization ofRS assay and theRSwere both strongly associated
with chemotherapy receipt. Patients eligible for
chemotherapy, based on NCCN criteria, were more likely to
receive chemotherapy if they did not undergo RS assay or
they had a high RS.
Keywords Breast cancer  21-Gene RS  Oncotype Dx 
NCDB  Adjuvant chemotherapy
Introduction
The use of predictive and prognostic multigene signature
testing (MGST) to aid in clinical decision-making regard-
ing adjuvant systemic therapy for breast cancer patients has
increased in the last decade as they have been incorporated
into clinical guidelines [1]. The 21-gene recurrence score
assay (RS assay) (OncotypeDX; Genomic Health Inc,
Redwood City, CA) quantifies risk of distant recurrence
and overall survival in patients with node-negative, estro-
gen receptor (ER)-positive breast cancer [2]. The primary
use of the RS assay in clinical practice in the United Sates
is to identify patients who may forego chemotherapy
without detriment to their disease outcome. Currently,
MGST is included in the National Comprehensive Cancer
Network (NCCN) guidelines for patients with ER-positive
and HER2-negative tumors who have undergone resection
and are candidates for chemotherapy [3]. The utility of RS
assay for this purpose has been evaluated in retrospective
and prospective clinical trials [2, 4, 5]. The impact of this
test on chemotherapy prescribing outside of clinical trials
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has been evaluated in single and multi-institutional studies
and in specific populations restricted by age, insurance
carrier, or geographic region [1, 6–8], but has not been
evaluated in clinical practice on a national scale with a
larger and more inclusive database such as the National
Cancer Data Base (NCDB). Our primary aim was to
evaluate the association between ordering the RS assay and
the recurrence score (RS) result with receipt of
chemotherapy in patients for whom NCCN guidelines
recommended RS assay. Along with this, we evaluated the
relationship between patient, facility, and tumor charac-
teristics with chemotherapy receipt.
Methods
Data source and study population
After approval by the NCDB, access was granted to the
NCDB registry Participant Use Data File (PUF) Breast
1998–2013. Patients were identified on the basis of Inter-
national Classification of Diseases for Oncology, 3rd edition
(ICD-O-3) site codes C50.0–C50.9 [9]. The NCDB is a
nationwide, facility-based, comprehensive clinical surveil-
lance resource oncology dataset started jointly in 1989 by the
Commission on Cancer (COC) of the American College of
Surgeons and the American Cancer Society. It is a clinical
oncology database that integrates hospital registry data that
are collected in more than 1500 COC-accredited facilities.
The American College of Surgeons has executed a Business
Associate Agreement, including data use, with each of its
COC-accredited hospitals. NCDB data are used to analyze
and track patients with malignant neoplastic diseases, their
treatments and outcomes. Data represent approximately
70 % of all newly diagnosed cancer cases nationwide
annually. The NCDB PUF is a Health Insurance Portability
and Accountability Act (HIPAA) compliant data file. Local
Institutional Research Board approval was waived for this
study because the PUF is a de-identified dataset and this was
a retrospective analysis.
For the current project, all patients with invasive breast
cancer diagnosed in years 2010–2013 were initially inclu-
ded. During this time period, the RS assay was incorpo-
rated into the NCCN guidelines as an option for patients
with early-stage ER-positive and HER2-negative breast
cancer when determining the utility of chemotherapy in
addition to endocrine therapy. Due to increase use of
MGST, the NCDB began requiring documentation of use
starting in 2010. We included only those patients who were
female and between the ages of 18–70 as the most repre-
sentative population of patients with breast cancer for
whom chemotherapy might be recommended. In order to
focus on those patients for whom NCCN would
recommend RS assay, we included those with ER-positive
or borderline and HER2-negative or borderline tumors that
were T1b-T3 and N0 or N1mi, overall AJCC stage 1 or 2
breast cancer with ductal, lobular, mixed, or metaplastic
histology. We excluded those with tubular and mucinous
histology since they are considered separately from the
aforementioned histology types in the NCCN guidelines
due to a more favorable prognosis. Patients who did not
undergo surgery were excluded as they would also not
meet NCCN guidelines for RS assay. Patients who received
chemotherapy or radiation therapy in the neo-adjuvant
setting and those for whom no information was available
regarding receipt of chemotherapy were also excluded.
The study population included patients who were eli-
gible for RS assay per NCCN guidelines and who had
information on receipt of chemotherapy. We excluded
patients who had no information as to whether the test was
ordered or who had a MGST ordered but the type was not
known or was other than RS. Remaining patients were
separated into those who had RS assay and RS (Group A)
and those who did not have an RS assay ordered (Group B).
Analysis regarding the association between RS and
chemotherapy receipt was performed on Group A. Matched
and unmatched analyses regarding differences in receipt of
chemotherapy between Group A and Group B were also
performed. See Fig. 1 for a consort diagram.
Variables
Patient, provider, facility, and tumor characteristics were
included in all our models. Age at diagnosis was categorized
as\40, 40–49, 50–59, and 60–70. Considering that age may
have an effect on clinician decision to use chemotherapy, an
interaction between age, RS, and chemotherapy receipt was
examined. RS was reported as either a numeric value or a
category as low risk (\18), intermediate risk (18–30), and
high risk ([30). Numerical reports were included in cate-
gorical reporting, but sole categorical reporting was exclu-
ded from our linear analysis. Race was categorized as black,
white (Hispanic and non-Hispanic), other, and unknown.
Ethnicity was further categorized as Mexicano/Chicano,
other Hispanic, non-Hispanic, and unknown or missing.
Number of comorbidities was derived from the Deyo adap-
tation of the Charlson comorbidity index [10]. Socioeco-
nomic data were provided as median household income
quartiles and percent of people without a high school degree
quartiles within the ZIP code where the patient resides.
County of residence was identified as rural (population
\2500), urban (population 2500–49,999), metro (population
[49,999), or unknown. We included only ductal, lobular,
mixed, and metaplastic histologic tumor types and catego-
rized them for ease of interpretation as ductal, lobular, or
other (mixed and metaplastic types) (See supplemental for
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histopathologic coding). We also identified cases as ER, PR,
and HER2 positive, negative, borderline, or unknown as
assigned by the COC category. T stage, N stage, and overall
stage were based on the American Joint Committee on
Cancer TNM staging manual (7th edition) for breast cancer
[11]. Grade was identified as well differentiated, moderately
differentiated, or poorly/undifferentiated. Treatment with
radiation was categorized as beam, implants, NOS,
radioisotopes, and other. Chemotherapy receipt is catego-
rized as ‘‘chemotherapy administered type and number of
agents not documented,’’ ‘‘single agent chemotherapy,’’
multi-agent chemotherapy,’’ ‘‘none,’’ ‘‘chemotherapy not
recommended/administered, contra-indicated due to patient
risk factors,’’ ‘‘Chemotherapy not administered, was rec-
ommended, not administered, reason unknown,’’ and
‘‘Chemotherapy not administered, was recommended, but
refused by patient, patient’s family member or guardian.’’
The first three categories were considered as chemotherapy
administered. The category ‘‘none’’ is chemotherapy not
recommended or administered.
Fig. 1 Consort flow diagram
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The facility type was assigned to quartiles according to
COC accreditation category based on annual total case
volume.
Statistics
Potential associations between patients’ demographic, tumor,
and facility features were initially assessed using Pearson v2
or Fisher exact tests for categorical data, and t tests or 1-way
analysis of variance for continuous data. Multivariate models
for receipt of chemotherapy were constructed via logistic
regression using a stepwise model selection process. During
the model selection process, a significance level of p\0.25
was required for initial variable entry into the model, while a
significance level of p\0.10 was required for the variable to
remain in the model during elimination steps. Propensity
score models of receipt of RS assay were constructed in a
similar manner, with recipients and non-recipients matched
on propensity score 1:1 using a greedy, nearest neighbor
matching algorithm and a maximum allowed propensity score
difference of ±2 %. A p value\0.05 was considered sig-
nificant for all comparisons, and all analyses were performed
using SAS 9.3 (SAS Institute Inc., Cary NC).
Results
There were 879,545 breast cancer patients identified in the
NCDB from 2010 to 2013. Of all patients whowere eligible for
MGST testing, an RS assay was ordered in 47 % of patients
(77,664/164,524). After appropriate exclusions as described
above, there were 132,651 patients who were eligible for RS
assay, compliant with NCCN guidelines and eligible for anal-
ysis.RSassaywasperformed in58.5 %ofeligiblepatientswith
results available (77,664/132,651). RS results were available
for 74,778 patients who were eligible for RS assay; among
those 60.9 % were low risk, 32.0 % intermediate risk, and
8.5 %high risk. Patientswith grade 1 tumors had highRS, only
1.4 %(281/19,810)of the time.Conversely, grade3 tumorshad
low RS, 29.1 % (3500/12,036) of the time.
Chemotherapy utilization in women with RS assay
(Group A)
On univariate analysis receipt of chemotherapy was associ-
ated with year of diagnosis (p\0.0001) and the following
patient features: age (p\0.0001), race (p\0.0001), insurance
status (p\0.0001), comorbidities (p\0.0001), and education
level (p = 0.001). There was also significant association
between each individual patient clinical characteristic and
receipt of chemotherapy (all p values\0.0001). After con-
trolling for other relevant demographic, clinical, and facility
features, the odds ratio for receipt of chemotherapy was
highest for the high RS category at 87.2 [(CI 79.6–95.6),
p\0.0001] followed by the intermediate RS category at 12.9
[(CI 21.2–13.6), p\0.0001] as compared to those in the low-
risk group (Fig. 2). When chemotherapy was recommended,
3161 out of 13,270 (23.8 %) patients in the intermediate-risk
group refused, 3342 out of 6024 (55.5 %) low-risk group
patients refused, and 364 out of 5863 (6.2 %) patients in the
high-risk group refused chemotherapy.
In separate multivariate analyses of patients with low and
intermediate RS for whom a numerical RS score was avail-
able, chemotherapy receipt was associated with younger age,
higher grade, higher T stage, or higher N stage. In both low-
and intermediate-risk groups, increasing RS score was sig-
nificantly associated with increasing odds of receiving
chemotherapy [OR 1.10 (CI 1.09–1.12), p\0.0001 and OR
1.26 (CI 1.25–1.27), p\0.0001, respectively, for each point
increase in RS]. See Fig. 3.
RS assay and chemotherapy utilization in women
eligible for RS testing (Groups A and B)
In 132,651 patients eligible for RS testing, utilization of RS
assay was highly significantly associated with all of the
patient tumor and demographic characteristics as listed in
Tables 1 and 2. The p values are based on tests of asso-
ciation between the demographic/clinical factor of interest
and a four-level variable which combines a patient’s
chemotherapy receipt status (yes/no) with the patient’s
receipt of RS testing status (yes/no). For example, a test of
association between the 4-level chemotherapy/RS status
and a demographic variable with three levels results in a
3 9 4 table and associated p value. From years 2010 to
2013, the utilization of RS assay in eligible patients
increased from 51.4 to 62.8 % and the receipt of
chemotherapy declined from 27.4 to 21.6 % (See Fig. 4).
In amultivariate logistic regression analysis of all patients
eligible for RS assay, after adjustment for relevant factors,
the group of patients who did not have the test was more
likely to receive chemotherapy OR 1.21 (CI 1.18–1.25,
p\0.0001) (Fig. 5). A confirmatory analysis based on 1:1
propensity score matching showed a similar significant
association between lack of RS assay and receipt of
chemotherapy [OR 1.18 (CI 1.15–1.22), p\0.0001 via
Pearson’s v2 test], with patients well matched with no sig-
nificant differences in patient tumor and demographic
characteristics shown previously in Tables 1 and 2.
Discussion
To our knowledge, this is the largest registry-based study
focused on the relationship between utilization of the RS
assay, RS, and receipt of chemotherapy, in chemotherapy-
318 Breast Cancer Res Treat (2016) 159:315–326
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eligible, early-stage breast cancer patients. In addition to
another year of data collection, our study provides a
focused propensity matched analysis on chemotherapy
receipt in contrast to a recently published study also eval-
uating NCDB data which provided a broad survey of
therapeutic implications and disparities associated with the
RS assay [12]. We found that both performing the test,
compared to not, and the RS itself was strongly associated
with chemotherapy receipt. Additionally, within the low
and intermediate RS groups a higher numerical value of the
RS was associated with chemotherapy receipt.
Before the introduction of MGST testing, evidence-
based guidelines for decision-making regarding
chemotherapy in breast cancer patients began after the
completion of multiple randomized cooperative studies,
which were later included in the Early Breast Cancer
Fig. 2 Forest plot, chemotherapy utilization in women with RS testing (Group A)
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Trialists Collaborative Group meta-analysis in 2005. Indi-
vidual trials and the meta-analysis demonstrated a benefit
of chemotherapy for all women with early-stage disease,
based on clinical–pathologic criteria [13]. Subsequently,
other investigators provided evidence of both the prog-
nostic (2004) and predictive (2006) value of the RS assay
[2, 14]. As a consequence, care guidelines changed,
acknowledging the potential utility of the RS assay for
decision-making. As early as 2007, the American Society
of Clinical Oncology (ASCO) described appropriate use of
the RS assay. Soon thereafter, the NCCN and others
incorporated the RS assay into their guidelines for
chemotherapy [3]. Recognizing the importance of the RS
assay and other types of MGST, the NCDB began to
capture data for them in 2010. There were at least four
reasons to do so. The first is to monitor for ‘‘appropriate-
ness’’ of ordering the test; i.e., are providers compliant with
the NCCN and other guidelines for ordering the test? Is
there under- or overutilization of the test itself? Recent
examples of inappropriate and unnecessary testing of dif-
ferent test types have been highlighted by ASCO in their
contributions to the Choosing Wisely campaign [15].
Second, if the test is ordered, do the results change pro-
vider’s behavior—and the patient–provider decision—to
use chemotherapy? Without monitoring, there is no way to
know if test results are changing practice. New tests are of
no value if their results do not influence the treatment
decisions for which the test was developed. Third, valida-
tion of the predictive function of the RS assay to determine
‘‘response’’ or ‘‘benefit’’ from chemotherapy requires
tracking of long-term cancer outcomes; i.e., is the overall
survival of patients—matched for clinical–pathologic fac-
tors—the same or different when patients with low RS and
no chemotherapy are compared to patients with low RS
who received chemotherapy? The NCDB is critical for
such a validation, due to its robust patient numbers and
demographic diversity. Lastly, a national dataset that
includes RS is necessary to search for inequities and dis-
parities for access to this important test. Jasem et al.
evaluated racial disparities in their analysis of the
2010–2012 NCDB [12].
We found that 58.5 % (77,664/132,651) of patients who
had data available and were NCCN criteria eligible for
testing were tested. We are unaware of any professional
organization that has yet endorsed a ‘‘benchmark’’ or
‘‘target’’ for the proportion of eligible patients that should
have the test ordered. Future investigations searching for
variability of use of the RS assay by provider, facility, and
other characteristics are warranted.
In a large meta-analysis, RS assay categorized 49, 39,
and 12 % of patients into low-, intermediate-, and high-risk
groups, respectively [16]. We found a significantly higher
rate of low-risk patients at 59.5 %, and lower rates of
intermediate- and high-risk patients at 32 and 8.5 %,
respectively, suggesting patients enrolled in clinical trials
may have higher risk features than those in standard US
clinical practice.
After adjustment for all other relevant factors, we
observed that patients who did not have RS assay testing
had significantly increased odds of receiving chemotherapy
Fig. 3 Proportion of all low-
and medium-risk patients with
and without chemotherapy, by
RS score
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Table 1 Study population demographics by chemotherapy receipt and RS testing
Received chemotherapy Did not receive chemotherapy P value*
Group A with RS
(n = 17,807)
Group B no RS
(13,612)
Group A with RS
(56,971)
Group B no RS
(41,375)
Age, years \0.0001
\40 1156 (6) 1274 (9) 1262 (2) 515 (1)
40–49 4594 (26) 3900 (29) 11,140 (20) 4928 (12)
50–59 6339 (36) 4506 (33) 19,320 (34) 11,694 (28)
60–70 5718 (32) 3932 (29) 25,249 (44) 24,238 (59)
Race \0.0001
White 15,151 (85) 11,219 (82) 50,249 (88) 35,979 (87)
Black 1629 (9) 1565 (12) 3957 (7) 3360 (8)
Other/unknown 1027 (6) 828 (6) 2765 (5) 2036 (5)
Ethnicity \0.0001
Mexican/Chicano/other 95 (1) 164 (1) 261 (1) 327 (1)
Hispanic 682 (4) 784 (6) 1957 (3) 1683 (4)
Non-Hispanic 16,284 (91) 12,188 (90) 52,329 (92) 37,889 (92)
Unknown/missing 746 (4) 476 (3) 2424 (4) 1476 (4)
Insurance status \0.0001
Private 13,224 (74) 9615 (71) 39,069 (69) 23,864 (58)
Medicare 2712 (15) 2022 (15) 12,693 (22) 13,443 (32)
Medicaid 1163 (7) 1287 (9) 3064 (5) 2356 (6)
Other government 195 (1) 155 (1) 626 (1) 439 (1)
Not insured/status unknown 513 (3) 533 (4) 1519 (3) 1273 (3)
Comorbidities (CDCC score) \0.0001
0 15,508 (87) 11,842 (87) 49,166 (86) 34,761 (84)
1 2039 (11) 1506 (11) 6667 (12) 5368 (13)
2 260 (2) 264 (2) 1138 (2) 1246 (3)
Year of diagnosis \0.0001
2010 3843(22) 3779 (27) 49,166 (86) 10,083 (25)
2011 4711 (27) 3653 (27) 6667 (12) 10,264 (25)
2012 4505 (25) 3232 (24) 1138 (2)) 10,543 (25)
2013 4748 (26) 2948 (22) 10,485 (25)
Income level (median) \0.0001
\$38,000 or not available 2129 (12) 1938 (15) 6742 (12) 5721 (14)
$38,000–$47,999 3456 (19) 2806 (20) 11,066 (19) 8545 (20)
$48,000–$62,999 4641 (26) 3679 (27) 15,268 (27) 11,045 (27)
C$63,000 7581 (43) 5189 (38) 23,895 (42) 16,064 (39)
Education (% without post high
school)
\0.0001
C21 2037 (11) 2082 (15) 6059 (10) 5636 (13)
13–20 3864 (22) 3135 (23) 11,894 (21) 9444 (23)
7–12.9 5897 (33) 4467 (33) 19,509 (34) 13,707 (33)
\7 or not available 6009 (34) 3928 (29) 19,509 (34) 12,588 (31)
Geographic location \0.0001
Metropolitan 15,111 (85) 11,428 (84) 48,162 (85) 34,547 (83)
Urban 2146 (12) 1743 (13) 7059 (12) 5379 (13)
Rural 128 (1) 100 (1) 423 (1) 297 (1)
Unknown 422(2) 341 (2) 1327 (3) 1152 (3)
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Table 1 continued
Received chemotherapy Did not receive chemotherapy P value*
Group A with RS
(n = 17,807)
Group B no RS
(13,612)
Group A with RS
(56,971)
Group B no RS
(41,375)
Facility type \0.0001
Academic/research 4050 (30) 18,987(33) 12,096 (29)
Non-academic 6405 (36)
11,402 (64)
9562 (70) 37,984 (67) 29,279 (71)
 All measurements reported as frequency and percent
* All p values are based on tests of association between the demographic characteristic and a 4-level variable of chemotherapy receipt (yes/no)
and RS assay (yes/no)
Table 2 Patient population clinical characteristics by chemotherapy receipt and RS testing
Received chemotherapy Did not receive chemotherapy P value*
Group A with RS
(n = 17,807)
Group B no RS
(13,612)
Group A with RS
(56,971)
Group B no RS
(41,375)
Histology \0.0001
Ductal 15,015 (84) 10,851 (80) 44,851 (79) 33,599 (81)
Lobular 1610 (9) 1635 (12) 7530 (13) 4663 (11)
Other 1182 (7) 1126 (8) 4590 (8) 3113 (8)
PR status \0.0001
Positive 14,276 (80) 11,024 (81) 53,583 (94) 37,878 (92)
Negative 3494 (20) 2554 (19) 3331 (6) 3412 (8)
Borderline 31 (\1) 27 (\1) 35 (\1) 61 (\1)
Not done/unknown 6 (\1) 7 (\1) 22 (\1) 24 (\1)
HER2¥ status \0.0001
Negative 17,371 (98) 13,086 (96) 56,118 (98) 40,470 (98)
Borderline 56,118 (2) 526 (4) 853 (2) 905 (2)
AJCC stage \0.0001
1B 2825 (16) 1459 (11) 14,427 () 19,282 (47)
1C 9165 (52) 5169 (38) 30,879 (54) 17,011 (41)
2 5586 (31) 6152 (45) 11,160 (20) 4818 (11)
3 231 (1) 832 (6) 505 (1) 264 (1)
Grade \0.0001
Well differentiated 2125 (12) 1719 (12) 17,685 (31) 16,953 (41)
Moderately differentiated 8300 (46) 5803 (43) 30,674 (54) 18,842 (45)
Poorly/undifferentiated 6514 (37) 5429 (40) 5522 (10) 3517 (9)
Not determined 868 (5) 661 (5) 3090 (5) 2063 (5)
Pathologic lymph node \0.0001
pN 0 15,488 (87) 10,357 (76) 51,716 (91) 39,318 (95)
pN 0? 863 (5) 892 (7) 2175 (4) 879 (2)
pN1mi 1456 (8) 2363 (17) 3080 (5) 1178 (3)
Radiation treatment \0.0001
Beam/implants/NOS 11,285 (63) 7353 (54) 37,733 (66) 26,292 (64)
Radioisotopes 2 (\1) 4 (\1) 35 (\1) 23 (\1)
None 6518 (37) 6255 (46) 19,200 (34) 15,056 (36)
Unknown 2 (\1) 0 (0) 3 (\1) 4 (\1)
 PR progesterone receptor
¥ HER2 human epidermal growth factor receptor 2
 All measurements reported as frequency and percent
* All p values are based on tests of association between the demographic characteristic and a 4-level variable of chemotherapy receipt (yes/no)
and RS assay (yes/no)
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(OR 1.21). Other studies have supported the ability of the
RS assay to change physician treatment recommendations
compared with those made on the basis of clinical patho-
logic characteristics alone, with a shift in recommendations
from chemotherapy and hormonal therapy to hormone
therapy alone. Reported reductions in chemotherapy use
range from 10 to 20 % with use of the assay [17–24],
although not all studies have reported declines in
chemotherapy use [22]. Using matched analysis, we found
an absolute reduction in chemotherapy receipt of 3 % when
RS assay was utilized. This corresponds to a number nee-
ded to test of 33 to forego chemotherapy use in one patient,
suggesting a significant impact in stewardship of limited
health care resources and cost of care. Over the 4-year
study period, we saw an overall decrease in chemotherapy
use with a corresponding increase in utilization of RS
assay.
The RS assay in previous work has been associated with
chemotherapy receipt in 10 % (low RS), 36 % (interme-
diate RS), and 72 % (high RS), although no clinical
pathologic correlates were available in these patients [25].
In our study, we observed grade 1 tumors had a high RS in
only 1.4 % of cases showing that a low grade can preclude
the need for RS testing. In comparison, the rates of
chemotherapy receipt in our analysis were significantly
lower in the low-risk group at 5 %, slightly higher rates in
intermediate-risk patients at 40 %, and an increased rate of
high-risk patients receiving chemotherapy at 85 %. These
results are similar to a prior investigation that captured
patients and testing from an insurance-claims database
linked to state cancer registries [6]. In this study, Potosky
et al. reported on 2362 patients less than 65 years of age
with invasive cancer. They found that 51, 39, and 10 % of
these women had low, intermediate, and high RS, of which
11, 47, and 88 %, respectively, received chemotherapy,
demonstrating a statistically significant direct relationship
between the RS and receipt of chemotherapy. On the other
hand, our findings differ from a recent analysis utilizing a
Surveillance, Epidemiology, and End Results (SEER)
dataset. Dinan et al. in a study limited to Medicare bene-
ficiaries observed no overall association between use of the
RS assay and receipt of chemotherapy; however, in an
unadjusted subset analysis, they did find a correlation
between the RS assay and lesser chemotherapy in patients
aged 66–70 years [7].
We observed that patients with low and intermediate
risk scores receiving chemotherapy more often if additional
clinical pathologic factors were present. We also found
concordance with a linear model of increasing receipt of
adjuvant chemotherapy as the absolute RS rose in both
low- and intermediate-risk patients after adjustments for all
other factors, supporting the previous observations of
Potosky et al. [6]. For example, we found that in the
intermediate group when the RS score increases from 20 to
30, the odds of a patient receiving chemotherapy increase
by a factor of 12.7. These results suggest that oncologists
are using the entire range of scores within the low- and
intermediate-risk group combined with clinical pathologic
risk factors to guide treatment decisions. As expected, the
low RS group had the highest rate of declining
chemotherapy when offered (56 %), likely based on per-
ceived lack of benefit of adjuvant chemotherapy—a finding
recently supported in a prospective clinical trial of node-
negative women [Trial Assigning Individualized Options
for Treatment (TAILORx)], wherein a similar low-risk
group had very low rates of recurrence at 5 years with
Fig. 4 Change over time in prevalence of 21-gene assay use and prevalence of chemotherapy use in the study population
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endocrine therapy alone [5]. Interestingly, 24 % of the
intermediate RS group declined chemotherapy after it was
offered, likely representing unclear benefits. Planned
analysis of intermediate group RS in the TAILORx trial is
designed to address the efficacy of chemotherapy in
women with Recurrence Score values from 11 to 25, but
results are still pending.
A strength of this study includes the sample size affor-
ded by the NCDB, allowing the majority of patients with
early-stage chemotherapy-eligible breast cancer in the
United States to be captured. Given this cohort, we were
able to adjust for the known confounding patient, tumor,
and facility factors that affect receipt of chemotherapy as
well as match similar patient groups.
Fig. 5 Forest Plot, RS assay, and chemotherapy utilization in women eligible for RS testing (Groups A and B)
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Our study has limitations. It has a retrospective study
design in which numerous patients had missing values for
RS. However, given the sample size of the NCDB, it is
unlikely that our findings would change, even with an
uneven distribution of the patients with missing RS values
between the low-, intermediate-, and high-risk groups. In
addition, unobserved confounding factors can limit inter-
pretation of study outcomes derived from observational
data. Some misclassification and treatment underreporting
are unavoidable in a large registry-based dataset like the
NCDB. The NCDB database does not provide information
regarding the intensity of ER expression (such as weakly
positive, 1?, 2?, 3?, or percentage ER positive) but rather
just categorizes ER as ‘‘positive,’’ ‘‘negative,’’ or ‘‘bor-
derline.’’ This is a limitation as many clinicians may have
used these intensity data to aid in deciding whether or not
to order a RS assay or recommend chemotherapy. Addi-
tionally, we could not assess the chemotherapy regimen
recommended or compare breast cancer recurrences, pro-
gression-free survival, or overall survival given the short
duration of MGST data in the NCDB and lack of outcome
data for less than 5 years in the NCDB. Earlier endpoints of
chemotherapy benefit, such as local or regional recurrence
rates, are not captured in the NCDB. Lastly, we are unable
to ascertain reasons for treating providers not obtaining a
RS assay or recommending for or against chemotherapy.
For instance, inherent bias may exist if oncologists are
more inclined to test early-stage breast cancer patients
whom they were considering for chemotherapy, such as
younger patients or those with higher grade tumors, and not
order tests for patients whom they intend to treat with
hormone therapy alone on the basis of more favorable
clinical pathologic features or patient unfitness or aversion
to chemotherapy. Alternatively, perhaps oncologists are
less likely to order a RS assay in younger patients who
have high-grade tumors that are only weakly ER positive as
they are uncomfortable foregoing chemotherapy in this
population. In fact, a bias among oncologists against
ordering a RS assay in these patients perceived to be at
higher risk based on pathologic characteristics may be
suggested by our finding of a lower percentage of patients
falling in the high-risk RS group as compared to previous
studies.
In conclusion, utilization of RS assay and RS was
strongly associated with chemotherapy receipt in a
nationally representative cohort of chemotherapy-eligible
women with early-stage breast cancer. Future investiga-
tions are warranted to clarify the optimal proportion of
eligible patients that should undergo RS assay testing. Until
then, the baseline percentage identified in the NCDB study
herein is 47 %.
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